Clinical Trials
11 trialsNCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01814046 2018-10-11
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00924287 2015-10-28
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00001832 2012-12-21
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00393029 2011-08-15
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001440 2008-03-04
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001705 2008-03-04
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
National Institutes of Health Clinical Center (CC)
Phase 2 Completed